MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients

University of Alberta215 enrolled

Overview

While many people with COVID-19 suffer from respiratory disease, there is growing evidence that the virus also affects other organs. The purpose of this study is to better understand the effects of COVID-19 on the lungs and other organs. The study investigators have developed new techniques in Magnetic Resonance Imaging (MRI) to scan the lungs, heart, brain and liver. The study investigators hope to learn more about how the virus causes inflammation in these organs and how this inflammation changes over time as people recover from COVID-19 illness. The study aims to enroll 228 people in Alberta. Participants will undergo one or more MRI scans and have blood testing at one or more time points to assess for inflammation, kidney function, liver function and possible heart injury. Participants will also undergo testing to assess sense of smell, cognition (thinking and memory), spirometry (breathing test for lung function) and and exercise tolerance (walk test). The study investigators hope this study will help us learn more about the long-term risks of COVID-19 disease.

Participants with newly or recently diagnosed COVID-19 infection (inpatients and outpatients) will undergo multi-organ MRI (heart, brain, lungs, liver), blood work, and functional testing at one or more time points. Functional testing will include olfaction testing, cognitive testing, spiromety, and a walk test.

Study Type

OBSERVATIONAL

Enrollment

215

Conditions

Covid19 Coronavirus Infection SARS-CoV Infection

MRI (heart, brain, lungs, liver)DIAGNOSTIC_TEST

MRI (heart, brain, lungs, liver)

BloodworkDIAGNOSTIC_TEST

Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA

Cognitive testingOTHER

NIH toolbox Cognitive Measures

Olfaction testingOTHER

Brief Smell Identification Test (BSIT)

SpirometryDIAGNOSTIC_TEST

Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity

Walk TestOTHER

Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Troponin substudy Inclusion Criteria: 1. 18 years of age or older 2. Willing and able to provide informed consent 3. COVID-19 positive test (within 14 days of positive test date) 4. High-sensitivity Troponin-I \>100ng/L or Troponin T \> 52ng/L 5. Ability to obtain Baseline MRI imaging within 7 days (up to 14 days maximum) of Troponin result Troponin substudy Exclusion Criteria: 1. Contraindication to MRI or MRI contrast 2. GFR \< 30ml/kg/min/1.73m2 3. Hemodynamic instability requiring inotropic agents 4. Active ventilatory support Late cross-sectional substudy Inclusion Criteria: 1. 18 years of age or older 2. Willing and able to provide informed consent 3. Previously diagnosed with COVID-19 \> 3 months ago 4. Ability to obtain MRI imaging at minimum 12 weeks from COVID-19 diagnosis Late cross-sectional substudy Exclusion Criteria: 1\. Contraindication to MRI or MRI contrast

Outcomes

Primary Outcomes

Native myocardial T1 relaxation time

Myocardial T1 is a surrogate marker of myocardial edema and the most sensitive MRI measure of acute myocarditis. We will show that myocardial T1 at baseline is significantly higher than myocardial T1 at 12 weeks follow-up. At 12 weeks, we will also compare native myocardial T1 in patients with baseline elevated troponin to those with baseline normal troponin as well as healthy controls